Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9ULA0
UPID:
DNPEP_HUMAN
Alternative names:
-
Alternative UPACC:
Q9ULA0; Q9BW44; Q9NUV5; Q9NV55
Background:
Aspartyl aminopeptidase, encoded by the gene with the accession number Q9ULA0, is a crucial enzyme in the process of protein metabolism. It specifically targets and cleaves acidic amino acids from the N-terminus of peptides, a step essential for the proper functioning of cellular mechanisms.
Therapeutic significance:
Understanding the role of Aspartyl aminopeptidase could open doors to potential therapeutic strategies. Its involvement in intracellular protein and peptide metabolism suggests its significance in maintaining cellular health and preventing disease.